We thank Dr. Frerichs and colleagues for their interest in our research letter (1). We used both experimental data and clinical findings in our study to demonstrate that an excessive level of positive end-expiratory pressure (PEEP) could be easily-and almost immediately by visual inspection-identified by detecting a distribution of ventilation being predominantly dorsal as compared with a frequently predominantly ventral ventilation in patients ventilated at lower PEEP. We suggest that decreasing PEEP in such cases to obtain a more equilibrated dorsal-to-ventral distribution can be proposed to patients right away. We also showed from experimental data that using compliance of the respiratory system for this purpose would be misleading.
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From the Authors:
We thank Dr. Frerichs and colleagues for their interest in our research letter (1) . We used both experimental data and clinical findings in our study to demonstrate that an excessive level of positive end-expiratory pressure (PEEP) could be easily-and almost immediately by visual inspection-identified by detecting a distribution of ventilation being predominantly dorsal as compared with a frequently predominantly ventral ventilation in patients ventilated at lower PEEP. We suggest that decreasing PEEP in such cases to obtain a more equilibrated dorsal-to-ventral distribution can be proposed to patients right away. We also showed from experimental data that using compliance of the respiratory system for this purpose would be misleading.
In our letter, we used the term "center of ventilation," as proposed in a previous study (2) . We appreciate Frerichs and colleagues' comment regarding the fact that this does not correspond to the most recent definition of center of ventilation, as indicated in a recent consensus statement (3) . We also acknowledge that using the center of ventilation, as proposed in that paper, requires a much more complex calculation than our own use of the distribution of ventilation. We believe that keeping this marker as simple as possible is important for clinical dissemination. We also believe that, based on the examples proposed, the center of ventilation as calculated from the reference value is much less clinically relevant for our purpose. We agree that a new denomination is needed for our index, and we propose the term "dorsal fraction of ventilation" as a better description. n Author disclosures are available with the text of this letter at www.atsjournals.org. hyperproliferative, apoptosis-resistant, and proinflammatory phenotype of microvascular endothelial cells and smooth muscle cells isolated from patients with pulmonary arterial hypertension (PAH). A previous study demonstrated that low-plasma highdensity lipoprotein cholesterol (HDL-C) was associated with higher mortality and clinical worsening outcomes, including hospitalization and lung transplantation in the patients with PAH (2). Administration of RVX-208 in the patients with coronary artery disease for 12 weeks was significantly associated with modulation of lipids metabolism, including increases in HDL-C level and concentration of large HDL particles (3). Hence, we considered whether, first, the change of HDL-C would be one feasible clinical biomarker to reflect the responsiveness of drugs or prognostic value in the patients with PAH. For example, the enhancement of HDL-C in plasma through RVX-208 treatment would improve the clinical outcomes in patients with PAH, and second, based on the beneficial effects of RVX-208 on the amelioration of vascular remodeling, pulmonary hemodynamics, and right ventricle in different preclinical models of PAH (1), the casual link among these observed outcomes, efficacy of RVX-208 therapy, and the change of HDL-C level or HDL components could be worthy of further investigation. Metabolic disorders characterized by increases of proinflammatory cytokine IL-6 level in lung and circulating leptin could exacerbate pulmonary hypertension as a result of left heart disease (PH-LHD), and patients diagnosed with this type of PAH have more severe symptoms and worse prognosis relative to patients with LHD alone (4) . Notably, in light of pulmonary vascular remodeling in such a novel preclinical model of PH-LHD relieved by metformin though improvement of metabolic states and decrease of inflammation, and positive effects of RVX-208 on the regulation of both inflammation and metabolism (3, 4) , we thought that providing more insights about the efficacy of RVX-208 in PH-LHD might be more favorable to its clinical use. Epigenetic regulation plays a key role in the pathogenesis of PAH, such as drug/toxin susceptibility, female predominance, and quasimalignant lung vessel cell growth (5) . In view of BET protein BRD4 (bromodomain-containing protein 4) as an epigenetic driver of inflammation and atherogenesis, the reduction of vascular inflammation in vitro and major adverse cardiac events in the patients with cardiovascular disease by the administration of RVX-208 has been considered to rely on a BET-dependent epigenetic mechanism (6) . Therefore, we considered that clarifying additional epigenetic mechanisms underlying the therapeutic process of RVX-208 in PAH might be in favor of identifying putative biomarkers and risk or resilience factors for making new-type prevention and treatment to answer epigeneticsensitive clinical challenges in PAH. n
